Breaking News

AMRI, GE Healthcare Extend Supply Pact

December 6, 2012

Will supply ABA product from Rensselaer facility

AMRI has extended a commercial supply agreement with GE Healthcare for Aminobisamide Hydrochloride (ABA), through December 31, 2016. AMRI will supply ABA, an intermediate material used in diagnostic imaging agents to GE. Production will continue at AMRI's large scale manufacturing subsidiary in Rensselaer, NY. The new contract replaces the existing supply contract initiated in 2005.
"We are pleased to once again extend our long-term relationship with GE Healthcare," said AMRI chairman, chief executive officer and president, Thomas E. D'Ambra, Ph.D. "The renewal of this relationship underscores the confidence that premier global pharmaceutical and health care companies have in AMRI's ability to meet their critical product needs."
"The ABA product relationship with GE Healthcare has been an important one for AMRI since acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement. We continue to be pleased with the progress that we are making in our Large Scale Manufacturing business segment, the largest component of which is our Rensselaer site. The extension of this key, long term agreement provides a consistent and high quality revenue source for this business unit through 2016."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments